/
PGEN
$5.92+$0.06 (+1.02%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.1B
357M shares
52-week range
$1.40 – $6.04
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-0.60
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $160.6M | $32.0M | $32.0M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Cost of revenue | $63.3M | $5.4M | $44.8M | $53.7M | $6.3M | $6.1M | $4.3M | $6.1M |
| Gross profit | $97.3M | $26.6M | −$12.8M | −$39.4M | $20.6M | $106.0K | −$342.0K | $3.6M |
| Gross margin | 60.6% | 83.2% | -40.0% | -276.2% | 76.4% | 1.7% | -8.7% | 37.1% |
| R&D | $404.6M | $39.4M | $39.4M | $47.9M | $47.2M | $48.6M | $53.1M | $40.1M |
| Operating income | −$505.6M | −$86.3M | −$86.3M | −$91.9M | −$75.7M | −$99.8M | −$135.0M | −$106.6M |
| EBITDA | −$349.1M | −$68.8M | −$68.0M | −$77.6M | −$62.4M | −$89.2M | −$123.5M | −$243.6M |
| Net income | −$509.3M | −$170.5M | −$170.5M | −$92.2M | $28.3M | −$95.9M | −$126.2M | −$250.6M |
| Net margin | -317.2% | -533.0% | -533.0% | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% |
| EPS (diluted) | -3.93 | -1.35 | -1.02 | -0.47 | -0.40 | -0.39 | -0.47 | -1.41 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $124M | $-0.03 | $-0.07–$0.03 | 2 |
| 2027 | $229M | $0.20 | $0.13–$0.27 | 2 |
| 2028 | $438M | $0.72 | $0.64–$0.82 | 1 |
| 2029 | $620M | $1.14 | $1.01–$1.30 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Precigen, Inc. Common Stock
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
www.precigen.com- Employees
- 47
- IPO / List date
- Aug 8, 2013
- HQ
- GERMANTOWN, MD
Held by traders on TradeandTell
No one on the platform currently holds PGEN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 287,403 | $408.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PGEN yet.
